Alliance Wealth Advisors (Utah)’s Vertex Pharmaceuticals VRTX Stock Holding History

Alliance Wealth Advisors (Utah)’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$764K	Sell	1,710 -634	-27%	-$296K	0.17%	93
2025 Q4	$1.06M	Sell	2,344 -554	-19%	-$239K	0.23%	93
2025 Q3	$1.13M	Buy	2,898 +753	+35%	+$315K	0.27%	103
2025 Q2	$955K	Buy	2,145 +572	+36%	+$264K	0.23%	102
2025 Q1	$763K	Buy	1,573 +638	+68%	+$297K	0.2%	114
2024 Q4	$377K	Buy	+935	New	+$433K	0.1%	192

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Alliance Wealth Advisors (Utah)'s VRTX Position: Q1 2026 in Review

Alliance Wealth Advisors (Utah) reduced its Vertex Pharmaceuticals (VRTX) stake by 27% in Q1 2026, selling an estimated $296K and leaving 1,710 shares worth $764K. The position accounts for 0.17% of the portfolio, ranked #93.

Alliance Wealth Advisors (Utah) first reported a position in VRTX in Q4 2024 and has held it in 6 quarters since. The position peaked at $1.13M in Q3 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Alliance Wealth Advisors (Utah) held 1,710 shares of Vertex Pharmaceuticals worth $764K as of Q1 2026.
Alliance Wealth Advisors (Utah) sold 634 Vertex Pharmaceuticals shares in Q1 2026, an estimated $296K.
Vertex Pharmaceuticals made up 0.17% of Alliance Wealth Advisors (Utah)'s portfolio in Q1 2026, its #93 holding.
Alliance Wealth Advisors (Utah) first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
Alliance Wealth Advisors (Utah)'s Vertex Pharmaceuticals position peaked at $1.13M in Q3 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Alliance Wealth Advisors (Utah)'s 13F filing for Q1 2026, filed 12 May 2026.